Tenax Therapeutics, Inc.
TENXNASDAQHealthcareBiotechnology
Previous close
$1.75
−$0.03 · -1.69%
TENX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
35
Expensive
Momentum
76
Gaining
Sentiment
69
Bullish
Risk resilience
56
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Christopher T. Giordano
- Listed since
- Apr 4, 1994
- Employees
- 15
Market position
Day range
Current $1.75
52-week range
Current $1.75
- Open
- $1.82
- Previous close
- $1.78
- Volume
- 4.15M
- 1.47× average
- Average volume
- 2.83M
- Average daily volume
- Market cap
- 46.42M USD
- Beta
- 0.93
- Market reference 1
- 50-day average
- $11.8413
- -85.22% below average
- 200-day average
- $12.1375
- -85.58% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -1.17×
- P/B (TTM)
- 0.78×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 32.67M USD | 12.71M USD | 3.23M USD | 5.38M USD | 25.15M USD |
| Selling, general, and administrative | 23.71M USD | 6.79M USD | 5.01M USD | 5.68M USD | 7.58M USD |
| Operating expenses | 56.39M USD | 19.49M USD | 8.23M USD | 11.05M USD | 32.73M USD |
| Interest income | 3.82M USD | 1.91M USD | — | — | — |
| Interest expense | — | 23K USD | 23.97K USD | 4.44K USD | 949 USD |
| Depreciation and amortization | — | — | 8K USD | 113.33K USD | 108.98K USD |
| Operating income | −56.39M USD | −19.49M USD | −8.23M USD | −11.05M USD | −32.73M USD |
| Net income | −52.6M USD | −17.6M USD | −7.71M USD | −11.05M USD | −32.47M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 82%
- 9 beats, 2 misses, 0 met estimates
- Average EPS surprise
- +28.94%
- 11 comparable reports
- Latest EPS result
- -0.35
- Estimate -0.38 · Beat by 8.20%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
TENX news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 3, 2024 | 1:80 | — | — |
Stock split | Jan 5, 2023 | 1:20 | — | — |
Stock split | Feb 26, 2018 | 1:20 | — | — |
Stock split | May 13, 2013 | 1:20 | — | — |
Stock split | Nov 9, 2009 | 1:15 | — | — |
Effective Jan 3, 2024
1:80
Effective Jan 5, 2023
1:20
Effective Feb 26, 2018
1:20
Effective May 13, 2013
1:20
Effective Nov 9, 2009
1:15
TENX peers
ETFs holding TENX
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI11.68M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF3.81M0.00%93.7B USD0.05%$245.53+0.82%
Vanguard Russell 2000 ETFVTWO1.94M0.01%17.4B USD0.06%$121.25+0.74%
iShares Russell 2000 ETFIWM1.15M0.00%81.62B USD0.19%$299.96+0.77%
iShares Russell 2000 Value ETFIWN423.64K0.00%14.66B USD0.24%$224.81+0.45%
Vanguard Russell 2000 Value ETFVTWV311.62K0.02%1.4B USD0.06%$198.38+0.34%
iShares Micro-Cap ETFIWC154.41K0.01%1.53B USD0.60%$198.39+1.10%
Dimensional - US Small Cap ETFDFAS122.26K0.00%15.92B USD0.26%$83.02+0.73%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 11.68M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 3.81M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Vanguard Russell 2000 ETFVTWO- Market value
- 1.94M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
iShares Russell 2000 ETFIWM- Market value
- 1.15M
- Weight
- 0.00%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
iShares Russell 2000 Value ETFIWN- Market value
- 423.64K
- Weight
- 0.00%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
Vanguard Russell 2000 Value ETFVTWV- Market value
- 311.62K
- Weight
- 0.02%
- AUM
- 1.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $198.38+0.34%
iShares Micro-Cap ETFIWC- Market value
- 154.41K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Dimensional - US Small Cap ETFDFAS- Market value
- 122.26K
- Weight
- 0.00%
- AUM
- 15.92B USD
- Expense ratio
- 0.26%
- Price / 1D
- $83.02+0.73%
Continue in GoAI
Research TENXresearch.disclaimer